Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06723119 · ClinicalTrials.gov registry record · NA

Effect of Resveratrol Supplementation on Exercise Performance and Recovery

A NA study of Effect of Resveratrol on Performance and Recovery, sponsored by University of Central Florida.

Recruiting
Registry status
NA
Development phase
20
Enrollment target
1
Study location

NCT06723119 is a NA study of Effect of Resveratrol on Performance and Recovery that is actively recruiting participants, run by University of Central Florida. The registered enrollment target is 20 participants. The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06723119, a NA study of Effect of Resveratrol on Performance and Recovery, is actively recruiting participants, sponsored by University of Central Florida.

RECRUITING
Registry status
NA
Development phase
20 participants
Enrollment target
1
Study location

Study Summary

To examine the effects of once daily supplementation with 500mg VeriSperse® resveratrol (VRES) for 17 days on muscle function, delayed onset muscle soreness, systemic concentrations of muscular damage markers and markers of oxidative stress in resistance trained young adult males following a damaging isoinertial squat protocol (ISP).

Interventions

  • OTHER Resveratrol (VRES) 500 mg oral once daily.
  • OTHER Placebo 500 mg oral once daily.

Study Locations (1)

Florida

  • University of Central Florida EPIC Lab - Orlando

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2024-10-01
Est. Completion 2025-04-01
Phase NA

Sponsor

University of Central Florida

91 total trials

What the Registry Record Tells You About NCT06723119

The ClinicalTrials.gov registry entry for NCT06723119 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Central Florida, which has 91 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Effect of Resveratrol on Performance and Recovery appearing as the primary indexed condition, and to 2 interventions - of which Resveratrol (VRES) 500 mg oral once daily. is the first listed.

NCT06723119 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.

Frequently Asked Questions

What is clinical trial NCT06723119 about?

NCT06723119 is a clinical study titled "Effect of Resveratrol Supplementation on Exercise Performance and Recovery". To examine the effects of once daily supplementation with 500mg VeriSperse® resveratrol (VRES) for 17 days on muscle function, delayed onset muscle soreness, systemic concentrations of muscular damage markers and markers of oxidative stress in resistance trained young adult males following a damagin...

What is the current status of trial NCT06723119?

This trial is currently recruiting. It is a NA study. The enrollment target is 20 participants. The study started on 2024-10-01. Estimated completion is 2025-04-01.

What conditions does trial NCT06723119 study?

This clinical trial studies the following conditions: Effect of Resveratrol on Performance and Recovery.

What interventions are being tested in trial NCT06723119?

The interventions under investigation include: Resveratrol (VRES) 500 mg oral once daily. (OTHER), Placebo 500 mg oral once daily. (OTHER).

Who is sponsoring clinical trial NCT06723119?

This trial is sponsored by University of Central Florida, which has 91 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06723119 being conducted?

This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.